Clinical trials: Ovary Disease
Endometrial Cancer, Gastrointestinal Stromal Tumor
STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
RATIONALE: STI571 may interfere with the growth of cancer cells and may be an effective treatment for soft tissue sarcoma. PURPOSE: Phase I/II trial to study the effectiveness of STI571 in treating patients who have recurrent or…
- Conditions
- Endometrial Cancer, Gastrointestinal Stromal Tumor, Ovarian Cancer, Sarcoma
- Trial name
- NCT00006357
- Testing
- imatinib mesylate
- Where
- 16 sites in Belgium, Denmark and 3 more
- Volunteers
- 91 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Ovarian Cancer
Fermented Wheat Germ Extract in Women With Ovarian Cancer
The main purpose of this Pilot Study is to test the safety, tolerability and quality of life in women who take Fermented Wheat Germ Extract (FWGE), to determine if an active form of FWGE can be detected in the blood, and…
- Trial name
- NCT02411565
- Testing
- Fermented Wheat Germ Extract (FWGE), Standard of Care: Planned Surgery, Quality of Life (QoL) Surveys: FACT-O
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Sarcoma, Multiple Myeloma
Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence
Positron Emission Tomography (PET) is a specialised nuclear medicine procedure that uses positron emitting radiolabeled tracer molecules to measure biological activity.
- Conditions
- Sarcoma, Multiple Myeloma, Testicular Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00123773
- Testing
- Positron Emission Tomography
- Where
- Canada
- Volunteers
- 1,075 people
- Sponsor
- AHS Cancer Control Alberta
Ovarian Cancer
Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.
Increasing number of ovarian cancer patients are receiving PARP inhibitor as maintenance or salvage therapy. Predictive factors to PARP inhibitor other than BRCA mutation or HRD status as well as specific resistance mechanism are…
- Trial name
- NCT05458973
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
HPEC, Ovarian Cancer
HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy
Ovarian cancer is the leading cause of gynecological cancer mortality, with no current screening method effective for early diagnosis, with 75% of advanced stage patients being detected.
- Conditions
- HPEC, Ovarian Cancer, Women's Health: Neoplasm of Ovary, Chemotherapy Effect
- Trial name
- NCT03275194
- Testing
- HIPEC
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Ovarian Cancer
Ovarian Screening Study
The objectives of this study are: To identify women at increased risk for developing ovarian cancer To detect ovarian cancers at an early stage To investigate the role of tumor membrane fragments as tumor markers for early…
- Trial name
- NCT00267072
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Ovarian Cancer
Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with surgery may kill more tumor cells.
- Trial name
- NCT00003695
- Testing
- chemotherapy, surgical procedure
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Medical Research Council
Ovarian Cancer, Fallopian Tube Cancer
SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care
This research study is testing the use of a smartphone app to identify clinically meaningful changes in the behaviors of patients' with gynecological cancers by using passively collected smartphone data.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
- Trial name
- SIGNAL (NCT04368130)
- Testing
- SIGNAL
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma of the Ovary, Fallopian Tube Cancer
Search for Predictors of Therapeutic Response in Ovarian Carcinoma
In order to search for predictors of response to chemotherapy in patients with ovarian carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage, we will define the comparative profiles of miRNA…
- Conditions
- Carcinoma of the Ovary, Fallopian Tube Cancer, Peritoneal Serous-type Advanced Stage
- Trial name
- miRSa (NCT01391351)
- Testing
- blood samples
- Where
- 7 sites in France
- Volunteers
- 107 people
- Sponsor
- Centre Francois Baclesse
Ovarian Cancer, Fallopian Tube Neoplasms
Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response
The purpose of this study is to use an immunologic approach following the treatment for recurrent disease in patients with ovarian, fallopian tube, or peritoneal cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT00103545
- Testing
- ACA 125
- Where
- 11 sites in Germany
- Volunteers
- 36 people
- Sponsor
- AGO Study Group
Cancer
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by…
- Trial name
- NCT00016380
- Testing
- dexamethasone, ondansetron, quality-of-life assessment
- Where
- 14 sites in Canada
- Volunteers
- 211 people
- Sponsor
- NCIC Clinical Trials Group
Medical Education, Ovarian Cancer
Ultrasound Training Program for Gynecologic Cancer Staging in Residents
This is a prospective, interventional study aiming to develop and validate an ultrasound training program for gynecology and obstetrics residents, focused on the staging of gynecologic cancers, including ovarian, endometrial, and…
- Conditions
- Medical Education, Ovarian Cancer, Endometrial Cancer, Cervix Cancer
- Trial name
- Ultra-teaching (NCT07028229)
- Testing
- Training Group
- Where
- Italy
- Volunteers
- 6 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Locally Advanced Solid Tumours, Metastatic Solid Tumours
Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
This Phase Ib study will identify the Maximum Tolerated Dose (MTD) of AZD1775 monotherapy when administered orally once daily (QD) or two times per day (BID) on Days 1 to 5 followed by 9 days of rest in 14-day cycles, or QD on a…
- Conditions
- Locally Advanced Solid Tumours, Metastatic Solid Tumours, Ovarian Cancer
- Trial name
- NCT02610075
- Testing
- AZD1775
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
Breast Cancer, Ovarian Epithelial Cancer Recurrent
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
This is a study to assess the safety of the combination of mifepristone and eribulin in patients with metastatic or locally advanced unresectable breast or other specified solid tumors, and determine preliminary efficacy of the…
- Conditions
- Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer
- Trial name
- NCT02014337
- Testing
- Mifepristone and Eribulin in combination
- Where
- 11 sites in United States
- Volunteers
- 37 people
- Sponsor
- Corcept Therapeutics
Polycystic Ovary Syndrome, Estro-progestin Drugs
Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome.
The estrogenic component of estro-progestin (EP) is responsible for a negative impact on the metabolic and lipid assessment in women with polycystic ovary syndrome (PCOS).
- Trial name
- NCT01519401
- Testing
- 3 mg drospirenone and 20 µg ethinyl-estradiol, 3 mg drospirenone and 30 µg ethinyl-estradiol
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Catholic University of the Sacred Heart
Ovarian Neoplasms
Biobehavioral-Cytokine Interactions in Ovarian Cancer
The purpose of this study is to understand relationships between behavioral factors, hormones, and chemicals produced by the body that may help tumor growth in ovarian cancer.
- Trial name
- VEGF (NCT01113112)
- Where
- 2 sites in United States
- Volunteers
- 613 people
- Sponsor
- Susan Lutgendorf
Body Weight, Polycystic Ovary Syndrome
The Effect of Obesity on Endometrium in PCOS
The effect of Polycystic Ovary Syndrome (PCOS) with or without obesity has received a few attentions. There is a lack of evidence to whether the BMI affects the endometrial blood flow, which is necessary for implantation.
- Trial name
- OB-PCO (NCT02694419)
- Testing
- Doppler evaluation
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Breast Cancer, Lung Cancer
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor…
- Conditions
- Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer
- Trial name
- TRT-001 (NCT02960594)
- Testing
- INO-1400, INO-9012, INO-1401
- Where
- 6 sites in United States
- Volunteers
- 93 people
- Sponsor
- Inovio Pharmaceuticals
Solid Tumors (Phase 1), Mesothelioma
Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if drug AROG4-01 is safe in patients with solid tumors who have no available treatment alternative. Different doses will be tested in order to identify the most suitable one.
- Conditions
- Solid Tumors (Phase 1), Mesothelioma, Colorectal Carcinoma, Ovarian Cancer
- Trial name
- AROG4-01-01 (NCT06652529)
- Testing
- AROG4-01
- Volunteers
- 35 people
- Sponsor
- Aromics Therapeutics
Ovarian Cancer, Primary Peritoneal Cancer
Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
This study will evaluate the efficacy and tolerability of the combination of Gleevec and Gemzar in patients with ovarian cancer, who have progressed after receiving at least one prior chemotherapy treatment.
- Trial name
- NCT00928642
- Testing
- imatinib mesylate by mouth, Gemcitabine Intravenous
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.